Study design of DIACORE (DIAbetes COhoRtE) – a cohort study of patients with diabetes mellitus type 2

BMC Medical Genetics

Carsten A Böger³  Iris M Heid⁴  Bernhard K Krämer²  Christoph Wanner⁵  Bernhard Banas³  Mathias Gorski¹  Vera Krane⁵  Alexander Lammert²  Lena Dörhöfer³ 

[1] Genetic Epidemiology, Department of Epidemiology and Preventive Medicine, University Regensburg, Franz-Josef-Strauß-Allee 11, 93042, Regensburg, Germany;Department of Medicine, Nephrology, Endocrinology, Diabetology, Rheumatology; Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Theodor Kutzer Ufer 1-3, 68167, Mannheim, Germany;Department of Internal Medicine II, Nephrology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93042, Regensburg, Germany;Institute of Genetic Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764, Neuherberg, Germany;Department of Internal Medicine I, Division of Nephrology, University Hospital Würzburg, Oberdürrbacherstraße 6, 97080, Würzburg, Germany

关键词: Genetics;    Epidemiology;    diabetes complications;    Cardiovascular morbidity;    End stage renal disease;    Chronic kidney disease;    Diabetic nephropathy;    Diabetes mellitus type 2;   

Others  :  1177729
DOI  :  10.1186/1471-2350-14-25

 received in 2012-09-29, accepted in 2013-01-25,  发布年份 2013

【 摘 要 】

Background

Diabetes mellitus type 2 (DM2) is highly associated with increased risk for chronic kidney disease (CKD), end stage renal disease (ESRD) and cardiovascular morbidity. Epidemiological and genetic studies generate hypotheses for innovative strategies in DM2 management by unravelling novel mechanisms of diabetes complications, which is essential for future intervention trials. We have thus initiated the DIAbetes COhoRtE study (DIACORE).

Methods

DIACORE is a prospective cohort study aiming to recruit 6000 patients of self-reported Caucasian ethnicity with prevalent DM2 for at least 10 years of follow-up. Study visits are performed in University-based recruiting clinics in Germany using standard operating procedures. All prevalent DM2 patients in outpatient clinics surrounding the recruiting centers are invited to participate. At baseline and at each 2-year follow-up examination, patients are subjected to a core phenotyping protocol. This includes a standardized online questionnaire and physical examination to determine incident micro- and macrovascular DM2 complications, malignancy and hospitalization, with a primary focus on renal events. Confirmatory outcome information is requested from patient records. Blood samples are obtained for a centrally analyzed standard laboratory panel and for biobanking of aliquots of serum, plasma, urine, mRNA and DNA for future scientific use. A subset of the cohort is subjected to extended phenotyping, e.g. sleep apnea screening, skin autofluorescence measurement, non-mydriatic retinal photography and non-invasive determination of arterial stiffness.

Discussion

DIACORE will enable the prospective evaluation of factors involved in DM2 complication pathogenesis using high-throughput technologies in biosamples and genetic epidemiological studies.

【 授权许可】

   
2013 Dörhöfer et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
• [2]Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T: Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005, 28:164-176.
• [3]Anand SS, Dagenais GR, Mohan V: Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. Eur J Prev Cardiol 2012, 19:755-764.
• [4]Bash LD, Astor BC, Coresh J: Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2010, 55:31-41.
• [5]Hardy DS, Hoelscher DM, Aragaki C: Association of glycemic index and glycemic load with risk of incident coronary heart disease among Whites and African Americans with and without type 2 diabetes: the Atherosclerosis Risk in Communities study. Ann Epidemiol 2010, 20:610-616.
• [6]Williams ME: Diabetic CKD/ESRD 2010: a progress report? Semin Dial 2010, 23:129-133.
• [7]Van Dijk PC, Jager KJ, Stengel B, Gronhagen-Riska C, Feest TG, Briggs JD: Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991–2000). Kidney Int 2005, 67:1489-1499.
• [8]Foley RN, Collins AJ: End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 2007, 18:2644-2648.
• [9]Centers for Disease Control and Prevention (CDC): Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes --- United States and Puerto Rico, 1996–2007. MMWR Morb Mortal Wkly Rep 2010, 59:1361-1366.
• [10]Keane WF, Brenner BM, de Zeeuw D: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003, 63:1499-1507.
• [11]Icks A, Haastert B, Genz J: Incidence of renal replacement therapy (RRT) in the diabetic compared with the non-diabetic population in a German region, 2002–08. Nephrol Dial Transplant 2011, 26:264-269.
• [12]Ismail-Beigi F, Craven T, Banerji MA: Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010, 376:419-430.
• [13]Gerstein HC, Miller ME, Byington RP: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
• [14]Patel A, MacMahon S, Chalmers J: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
• [15]Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998, 352:837-853.
• [16]Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group BMJ 1998, 317:703-713.
• [17]Haller H, Ito S, Izzo JL Jr: Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011, 364:907-917.
• [18]Reaven PD, Moritz TE, Schwenke DC: Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes 2009, 58:2642-2648.
• [19]Agrawal L, Azad N, Emanuele NV: Observation on renal outcomes in the veterans affairs diabetes trial. Diabetes Care 2011, 34:2090-2094.
• [20]Lewis EJ, Hunsicker LG, Clarke WR: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
• [21]Placha G, Canani LH, Warram JH, Krolewski AS: Evidence for different susceptibility genes for proteinuria and ESRD in type 2 diabetes. Adv Chronic Kidney Dis 2005, 12:155-169.
• [22]Sladek R, Rocheleau G, Rung J: A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007, 445:881-885.
• [23]Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-678.
• [24]Böger C, Gorski M, Li M: Association of eGFR-related loci identified by GWAS with incident CKD and ESRD. PLoS Genet 2011, 7:1-8.
• [25]Böger CA, Chen MH, Tin A: CUBN Is a Gene Locus for Albuminuria. J Am Soc Nephrol 2011, 22:555-570.
• [26]Köttgen A, Glazer NL, Dehghan A: Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet 2009, 41:712-717.
• [27]Köttgen A, Pattaro C, Böger CA: New loci associated with kidney function and chronic kidney disease. Nat Genet 2010, 42:376-384.
• [28]Böger C, Heid I: Chronic Kidney Disease: Novel Insights from Genome Wide Association Studies. Kidney Blood Press Res 2011, 34:27-36.
• [29]McCarthy MI, Abecasis GR, Cardon LR: Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008, 9:356-369.
• [30]The National Cohort. A prospective epidemiologic study resource for health and disease research in Germany. 2011. http://www.nationale-kohorte.de/content/wissenschaftliches_konzept_der_nationalen_kohorte.pdf webcite. Accessed March 26, 2012.
• [31]Baumeister SE, Böger CA, Krämer BK: Effect of chronic kidney disease and comorbid conditions on health care costs: A 10-year observational study in a general population. Am J Nephrol 2010, 31:222-229.
• [32]Almgren P, Lehtovirta M, Isomaa B: Heritability and familiality of type 2 diabetes and related quantitative traits in the Botnia Study. Diabetologia 2011, 54:2811-2819.
• [33]Pearson ER, Donnelly LA, Kimber C: Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007, 56:2178-2182.
• [34]Igo RP Jr, Iyengar SK, Nicholas SB: Genomewide linkage scan for diabetic renal failure and albuminuria: the FIND study. Am J Nephrol 2011, 33:381-389.
• [35]Eckardt KU, Barthlein B, Baid-Agrawal S: The German Chronic Kidney Disease (GCKD) study: design and methods. Nephrol Dial Transplant 2011, 27:1454-1460.
• [36]Schaeffner ES, van der Giet M, Gaedeke J: The Berlin initiative study: the methodology of exploring kidney function in the elderly by combining a longitudinal and cross-sectional approach. Eur J Epidemiol 2010, 25:203-210.
• [37]Querfeld U, Anarat A, Bayazit AK: The Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C) study: objectives, design, and methodology. Clin J Am Soc Nephrol 2010, 5:1642-1648.
• [38]WHO 2011. http://www.who.int/diabetes/publications/report-hba1c_2011.pdf webcite (Accessed on June 07, 2011
• [39]WHO 2011. http://whqlibdoc.who.int/publications/2006/9241594934_eng.pdf webcite (Accessed on December 22, 2011)
• [40]American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33 Suppl 1:S62-69.
• [41]Pischon T, Boeing H, Hoffmann K: General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008, 359:2105-2120.
• [42]Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
• [43]Levey AS, Coresh J, Greene T: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006, 145:247-254.
• [44]Levey AS, Stevens LA, Schmid CH: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.
• [45]Böger CA, Kronenberg F: How healthy are your vessels?–Check your urine! Atherosclerosis 2012, 220:38-41.
• [46]Stevens LA, Coresh J, Schmid CH: Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008, 51:395-406.
• [47]Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63:225-232.
• [48]Palmer CN, Kimber CH, Doney AS: Combined effect of inflammatory gene polymorphisms and the risk of ischemic stroke in a prospective cohort of subjects with type 2 diabetes: a Go-DARTS study. Diabetes 2010, 59:2945-2948.
• [49]Ahluwalia TS, Lindholm E, Groop LC: Common variants in CNDP1 and CNDP2, and risk of nephropathy in type 2 diabetes. Diabetologia 2011, 54:2295-2302.
• [50]Mann JF, Schmieder RE, McQueen M: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553.
• [51]The SYSKID Consortiumhttp://www.syskid.eu webcite. Accessed March 26, 2012
• [52]Preis SR, Pencina MJ, Hwang SJ: Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation 2009, 120:212-220.
• [53]Fox CS, Larson MG, Leip EP, Meigs JB, Wilson PW, Levy D: Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care 2005, 28:2436-2440.
• [54]Mazzucco G, Bertani T, Fortunato M: Different patterns of renal damage in type 2 diabetes mellitus: a multicentric study on 393 biopsies. Am J Kidney Dis 2002, 39:713-720.
• [55]Haider DG, Peric S, Friedl A: Kidney biopsy in patients with diabetes mellitus. Clin Nephrol 2011, 76:180-185.
• [56]Suzuki D, Takano H, Toyoda M: Evaluation of renal biopsy samples of patients with diabetic nephropathy. Intern Med 2001, 40:1077-1084.
• [57]Parving HH, Gall MA, Skott P: Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 1992, 41:758-762.
• [58]Molitch ME, Steffes M, Sun W: Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 2010, 33:1536-1543.
• [59]Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR: Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006, 55:1832-1839.
• [60]Kramer HJ, Nguyen QD, Curhan G, Hsu CY: Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003, 289:3273-3277.
• [61]Perkins BA, Ficociello LH, Ostrander BE: Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007, 18:1353-1361.
• [62]Costacou T, Ellis D, Fried L, Orchard TJ: Sequence of progression of albuminuria and decreased GFR in persons with type 1 diabetes: a cohort study. Am J Kidney Dis 2007, 50:721-732.
• [63]Ellis JW, Chen MH, Foster M: Validated SNPs for eGFR and their Associations with Albuminuria. Hum Mol Genet 2012. in press
• [64]Suhre K, Shin SY, Petersen AK: Human metabolic individuality in biomedical and pharmaceutical research. Nature 2011, 477:54-60.
• [65]Gronwald W, Klein MS, Zeltner R: Detection of autosomal dominant polycystic kidney disease by NMR spectroscopic fingerprinting of urine. Kidney Int 2011, 79:1244-1253.
• [66]Hindorff LA JH, Hall PN, Mehta JP, Manolio TA: A Catalog of Published Genome-Wide Association Studies. 2012. Available at: http://www.genome.gov webcite Accessed February 3
• [67]Gudbjartsson DF, Holm H, Indridason OS: Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases. PLoS Genet 2010, 6:e1001039.
• [68]Pattaro C: Genome-wide assocation and functional follow-up reveals new loci for kidney function. PLoS Genet 2012, 8:1-13.
• [69]Köttgen A, Hwang SJ, Larson MG: Uromodulin levels associate with a common UMOD variant and risk for incident CKD. J Am Soc Nephrol 2010, 21:337-344.